This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Mylotarg™​​​​​​​​​​​​​​▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.

AML Landscape: Present and Future Video

Speaker: Dr Eleni Tholouli

Duration: 02.23

In this video, Dr. Tholouli discusses Mylotarg’s NICE approval and its practical approach to the issue of waiting for cytogenics and Mylotarg’s use1. Dr Tholouli also mentions results in event free survival and relapse risk alongside the safety data2. Practical considerations using the ALFA schedule, platelet recovery, risk of VOD and minimising risks to the liver are also considered2.

Dr. Eleni Tholouli is a Consultant Haematologist at Manchester University NHS Trust and Director of the Adult Stem Cell Transplant Unit. She is a member of the Haemato-Oncology Pathway Board at Manchester Cancer and of national bodies such as the AML Working Group and the Blood and Marrow Transplantation Clinical Reference Group. Her expertise covers a wide range of haemato-oncological malignancies and non-malignant disorders.

Explore more 

Efficacy and Safety of MYLOTARG video

Watch Professor Robert Hills discuss the key clinical data from the pivotal ALFA study

Learn more

Fast Facts

Download the Fast Facts PDF document to aid your understanding of MYLOTARG

View Fast Facts PDF
AML, Acute Myeloid Leukaemia
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
  1. NICE Technology Appraisal Guidance (TA545). Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. Available at: https://www.nice.org.uk/guidance/TA545/history. Published: 14 November 2018. Accessed March 2021.
  2. MYLOTARG Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9151/smpc. Accessed March 2021.
PP-MYL-GBR-0238. March 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now
Quick Links

Understand the evidence

Guidelines

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No